We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

62 hedge funds and large institutions have $45.1M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

10% more capital invested

Capital invested by funds: $41.1M → $45.1M (+$3.97M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 66 → 62 (-4)

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

Holders
62
Holders Change
-4
Holders Change %
-6.06%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
27
Reduced
14
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
+$4.08M
2
CCM
CAAS Capital Management
New York
+$2.69M
3
MF
Magnetar Financial
Illinois
+$2.46M
4
Morgan Stanley
Morgan Stanley
New York
+$1.4M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.08M

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.04M
2
EP
Eversept Partners
New York
-$532K
3
AQR Capital Management
AQR Capital Management
Connecticut
-$332K
4
JIC
Joel Isaacson & Co
New York
-$303K
5
BlackRock
BlackRock
New York
-$274K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$314K +$335K +58,102 New
SGAM
27
Smith Group Asset Management
Texas
$281K +$300K +52,020 New
BFM
28
Boothbay Fund Management
New York
$273K +$291K +50,443 New
Goldman Sachs
29
Goldman Sachs
New York
$270K -$43.5K -7,550 -13%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$223K +$72.6K +12,597 +44%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$195K +$114K +19,870 +123%
Wells Fargo
32
Wells Fargo
California
$150K +$96.7K +16,781 +154%
FA
33
Forefront Analytics
Pennsylvania
$111K +$119K +20,655 New
HW
34
Hancock Whitney
Mississippi
$100K -$23K -4,000 -18%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$100K +$2.24K +389 +2%
QSS
36
Quantitative Systematic Strategies
Florida
$85K +$90K +15,620 New
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$76K -$12.4K -2,151 -13%
PP
38
PDT Partners
New York
$71K +$75.8K +13,165 New
AIM
39
Alambic Investment Management
California
$68K -$204K -35,456 -74%
ProShare Advisors
40
ProShare Advisors
Maryland
$64K +$4.79K +832 +8%
MAM
41
Meeder Asset Management
Ohio
$61K – – –
AIG
42
American International Group
New York
$42K +$2.48K +430 +6%
TRCT
43
Tower Research Capital (TRC)
New York
$36K +$9.43K +1,638 +33%
Deutsche Bank
44
Deutsche Bank
Germany
$33K +$3.15K +547 +10%
Barclays
45
Barclays
United Kingdom
$32K -$3.93K -682 -10%
JP Morgan Chase
46
JP Morgan Chase
New York
$26K +$4.73K +822 +20%
PAM
47
Panagora Asset Management
Massachusetts
$24K -$247K -42,956 -91%
Citigroup
48
Citigroup
New York
$24K -$4.78K -829 -16%
Federated Hermes
49
Federated Hermes
Pennsylvania
$18K +$17.9K +3,101 +1,391%
SO
50
STRS Ohio
Ohio
$14K – – –
1
2
3 4

RVLP Hedge Fund Activity: Q3 2020 in Review

62 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2020, worth a combined $45.1M — up 9.7% from $41.1M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RVLP and 13 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 27 added.

The largest buyer was DG Capital Management, adding an estimated $4.08M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.04M sold.

  • 62 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2020, down from 66 in Q2 2020.
  • Funds reported $45.1M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2020, up 9.7% quarter-over-quarter.
  • 13 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2020 and 17 closed out, a net change of -4 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2020 was DG Capital Management, an estimated $4.08M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2020 was Acadian Asset Management, an estimated $1.04M sold.

Based on aggregated 13F filings for Q3 2020.